POZEN Pharmaceutical Development Company

	December 03, 2009 POZEN to Host Investor and Analyst Event on December 8, 2009

	November 20, 2009 POZEN Announces Start of Enrollment For PA32540 Phase 3 Program

	Webcast - Replay POZEN Inc. at The Credit Suisse Phoenix Healthcare Conference November 13, 2009 at 8:30 AM PT

POZEN is a pharmaceutical company committed to transforming medicine that transforms lives.

UBS Global Life Sciences Conference
September 21, 2009

Advancing the Power of Aspirin:
A POZEN Inc. Analyst and Investor Event
December 8, 2009

Information on Participating in a
POZEN Clinical Trial

02/08/10 4:00 p.m. ET
NASDAQ: Pozen	$5.58

Change: - 0.26	4.45%
Volume: 40,727